Agreement covers protein-alkylating, tumour-activated pro-drug payload series for ADC development
Company signs deals with two specialist pharmaceutical manufacturers
Participant in phase III study developed unexplained illness
Updated Date: Tue, 06 Oct 2020 00:00:00 EDT
Updated Date: Tue, 06 Oct 2020 00:00:00 EDT
Updated Date: Tue, 06 Oct 2020 00:00:00 EDT
Updated Date: Tue, 06 Oct 2020 00:00:00 EDT
Updated Date: Tue, 06 Oct 2020 00:00:00 EDT
Doshi discusses the studies that have shown pre-existing immunity to SARS-CoV-2.[3] Most governments have based their decisions in […]
The government may reintroduce advice for clinically extremely vulnerable people to shield from covid-19 if they live in […]